R-PMDT Regimen in Newly Diagnosed PCNSL
Recruiting
Phase 2
Interventional Study
Primary Central Nervous System (CNS) Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 33 (estimated)
- Sponsor
- Zou Dehui · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A total of six cycles of the R-PMDT regimen (rituximab, pirtobrutinib, high-dose methotrexate, dexamethasone, and thiotepa) will be administered to patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The primary objective is to assess the overall response rate (ORR) of R-PMDT. Secondary objectives include evaluating the complete response rate, progression-free survival (…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Newly diagnosed primary central nervous system diffuse large B-cell lymphoma
* Adequate hematologic function: ANC ≥1.0×10⁹/L, PLT ≥75×10⁹/L
* Adequate hepatic function: ALT/AST ≤3×ULN; total bilirubin ≤1.5×ULN
* Adequate renal function: serum creatinine ≤2×ULN or CrCl ≥40 mL/m…